Changeflow GovPing Pharma & Drug Safety Substituted Entecavir Monophosphate Alaninamide...
Routine Notice Added Final

Substituted Entecavir Monophosphate Alaninamide Phenolic Esters for Hepatitis B

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted Patent No. US12590097B2 to Beijing Junke Huayuan Med Tech Co., Ltd. on March 31, 2026, covering entecavir monophosphate alaninamide phenolic ester derivatives for hepatitis B treatment. The patent grants exclusive rights to the pharmaceutical compound for resisting hepatitis B virus. This is a routine patent grant notification.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued Patent No. US12590097B2 to Beijing Junke Huayuan Med Tech Co., Ltd. for a substituted entecavir monophosphate alaninamide phenolic ester compound effective against hepatitis B virus. The patent, filed April 1, 2021, covers 11 claims including the compound of formula II, its non-toxic salts, and methods of using the derivative for preparing antiviral drugs.

Pharmaceutical companies developing or manufacturing hepatitis B treatments should verify whether their products or compounds fall within the scope of this patent. Patent grants do not impose compliance deadlines but establish enforceable intellectual property rights that could affect freedom to operate in this therapeutic area.

Archived snapshot

Mar 31, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Substituted entecavir monophosphate alaninamide phenolic esters for resisting hepatitis b virus

Grant US12590097B2 Kind: B2 Mar 31, 2026

Assignee

BEIJING JUNKE HUAYUAN MED TECH CO., LTD.

Inventors

Bohua Zhong, Hongwu Li, Xiaozai Wang

Abstract

An entecavir monophosphate alaninamide phenolic ester derivative is represented by formula II. It has non-toxic pharmaceutically acceptable salts. In formula II, X is H, halogen, R or —OR, and R is a C1-3 alkyl or a substituted C1-3 alkyl. The entecavir monophosphate alaninamide phenolic ester derivative or the non-toxic pharmaceutically acceptable salt thereof can be used in the preparation of a drug for resisting the hepatitis B virus.

CPC Classifications

A61K 31/522 C07D 487/04

Filing Date

2021-04-01

Application No.

17907684

Claims

11

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12590097B2

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!